IMV organizacji Rok IPO
Jaka jest wartość Rok IPO organizacji IMV?
Wartość Rok IPO organizacji IMV, Inc. to 2012
Jaka jest definicja Rok IPO?
Pierwsza oferta publiczna jest rodzajem oferty publicznej, w której akcje spółki zazwyczaj sprzedawane są inwestorom instytucjonalnym, którzy z kolei sprzedają się ogółowi społeczeństwa, na giełdzie papierów wartościowych, po raz pierwszy.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Rok IPO firm w Health Care sektor na TSX w porównaniu do IMV
Czym się zajmuję organizacja IMV?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Firmy z rok ipo podobne do IMV
- Wartość Rok IPO organizacji American Century ETF Trust to 2011
- Wartość Rok IPO organizacji Sino Harbour to 2011
- Wartość Rok IPO organizacji Horizons Gold Prod Equty Cvrd C to 2011
- Wartość Rok IPO organizacji HFX to 2011
- Wartość Rok IPO organizacji Dark Horse Resources to 2011
- Wartość Rok IPO organizacji Om Metals Infraprojects to 2011
- Wartość Rok IPO organizacji IMV to 2012
- Wartość Rok IPO organizacji Evertec Inc to 2013
- Wartość Rok IPO organizacji Virtus Health to 2013
- Wartość Rok IPO organizacji Antero Resources Corp to 2013
- Wartość Rok IPO organizacji Murphy USA Inc to 2013
- Wartość Rok IPO organizacji Kodal Minerals Plc to 2013
- Wartość Rok IPO organizacji Agios Pharmaceuticals Inc to 2013